Quetiapine fumarate is an antipsychotic drug with plasma half-life 6 hr. and having poor oral
bioavailability (9%) because of first pass metabolism. The aim of the present study was to …

Quetiapine fumarate is an antipsychotic drug with poor oral bioavailability (9%) due to first‐
pass metabolism. Present work is an attempt to improve oral bioavailability of quetiapine …

Quetiapine fumarate (QF) is an atypical antipsychotic, undergoing extensive first pass
metabolism and hence shows lower bioavailability orally. Solid Lipid Nanoparticles (SLNs) …

Quatiepine, an effective atypical anti psychotic administered as fumarate or hemifumarate
salts by intravenous injection shows poor brain uptake due to low partitioning and/or Pgp …

Aims: The study aimed at developing and characterizing Nanostructured Lipid Carriers
(NLC) of Quetiapine Fumarate (QF) by Design of Experiment (DoE) for the enhancement of …

Poorly water soluble drugs such as quetiapine fumarate (QF) offer challenges in developing
a solid dosage form such as tablets with adequate bioavailability. The objective of the …

Background: Quetiapine fumarate, a 2nd generation anti-psychotic drug has oral
bioavailability of 9% because of hepatic first pass metabolism. Reports suggest that co …

Abstract Aim: Nanostrucured Lipid Carriers (NLCs) are the 2nd generation of Solid Lipid
Nanoparticles (SLNs) designed to overcome limitations of SLNs. Their characteristics can be …

Quetiapine Hemifumarate is a Anti-Psychotic drug used for the treatment of Schizophrenia
and Bi-polar disorder with an oral bioavailability of 9%. The present research investigation …

The aim of present study is to investigate the potential of nanostructured lipid carriers (NLCs)
in improving the oral bioavailability of quetiapine fumarate, a second-generation …